KAHR-102 is expected to initiate clinical trials in early 2016.
Mode of action –
KAHR-102 is a fusion protein that links portions of two immune and cancer-related membrane proteins; CTLA-4 and FasL.
The functions of KAHR-102 in immune settings are anticipated from its component parts; The CTLA-4 component of KAHR-102 binds to B7 costimulators on antigen-presenting-cells (APC), such as dendritic cells, and thereby prevents them from engaging and triggering their cognate stimulatory CD28 receptor on T cells. The FasL component of the KAHR-102 fusion protein, binds to its cognate Fas receptor, which is upregulated on activated T cells, and thereby triggers apoptosis in these cells. The net effect of combining these blocking and triggering functions is to convert a T cell activating signal into an inhibitory one, leading to immune suppression.
KAHR-102 has also shown significant activity in cancer - both in-vitro and in cancer animal models. The CTLA-4 side of the drug targets to B7 receptors on lymphatic cancer cells, while the FasL side of the drug induces specific apoptosis of these cancer cells.
KAHR-102 forms a homo-hexamer which allows an optimal hexameric FasL structure to be specifically targeted to B7-expressing cells, such as in lymphoma cells.
R&D Status -
KAHR-102 has been extensively investigated for more than 15 years and has exhibited efficacy both in-vitro and in multiple animal models. The data of these investigations has been published in multiple scientific publications.
Production process development and toxicology studies in animals have been successfully completed. The pre-clinical file for KAHR-102 was recently submitted to the Israeli regulatory authorities and the first clinical trial for the treatment of lymphatic cancer is expected to initiate in mid 2016 in Israel